AbbVie, Inc., submitted a notification of proposed production activity to the FTZ Board (the Board) for its facilities in Chicago, Illinois within Subzone 22S. The notification conforming to the requirements of the Board's regulations (15 CFR 400.22) was received on April 29, 2022.
Pursuant to 15 CFR 400.14(b), FTZ production activity would be limited to the specific foreign-status material and specific finished product described in the submitted notification (summarized below) and subsequently authorized by the Board. The benefits that may stem from conducting production activity under FTZ procedures are explained in the background section of the Board's website—accessible via www.trade.gov/ftz . The proposed finished product and material would be added to the production authority that the Board previously approved for the operation, as reflected on the Board's website.
The proposed finished product is prolinamide tablets (duty-free).
The proposed foreign-status material is prolinamide active pharmaceutical ingredient (duty rate 3.7%).
Public comment is invited from interested parties. Submissions shall be addressed to the Board's Executive Secretary and sent to: ftz@trade.gov . The closing period for their receipt is June 21, 2022.
A copy of the notification will be available for public inspection in the “Online FTZ Information System” section of the Board's website.
For further information, contact Christopher Wedderburn at Chris.Wedderburn@trade.gov .
Dated: May 4, 2022.
Andrew McGilvray,
Executive Secretary.
[FR Doc. 2022-09876 Filed 5-6-22; 8:45 am]
BILLING CODE 3510-DS-P